drkazmd65... With all due respect to your knowledge and background, I believe the date and context of this older report attached, does indeed progress historically to last weeks timely use of the zMapp drug. My question is, who or what company is responsible for the zMapp serum? What is that company's track record and what are the US Governments financial relationships with such company? Ebola and HIV/HPV are different but very deadly viruses.
The last line of the second paragraph is a zinger. Not to mention investor glee for last line of third paragraph.
Re: Cel-Sci corporation CVM
Berichtdoor rood&wit » 07 Feb 2014 15:33
Navy CRADA Fast-Tracks Cel-Sci's Immunotherapy For HPV
With recent news of an upcoming clinical trial, CEL-SCI Corporation (CVM) proves to be one of the best bets on the fast track of immunotherapy, drugs using the body's own natural defenses to fight disease. Its latest win is approval from the US Navy to begin a dose escalation Phase I study using Multikine, the company's proprietary version of small proteins that regulate immune response and inflammation, in men and women suffering from both HIV and human papilloma virus (HPV) that have developed unsightly and potentially dangerous warts around the anus. HPV is particularly insidious because of the lack of overt symptomology, making it the commonest of sexually-transmitted diseases.
Just last fall, CEL-SCI signed a Cooperative Research and Development Agreement (CRADA) with the Naval Medical Center in San Diego, CA, a center of excellence in HIV and AIDS care with more than 30 clinical trials done to date, for a human study pursuant to approval from the Navy's Institutional Review Board (IRB) consisting of a body of experts that sanction clinical trials. This has been achieved, allowing immediate patient enrollment. Along with peri-anal warts, Multikine's effect on anal intraepithelial dysplasia, a forerunner to anal cancer, will be measured. The study will not take long with results expected this year.
Initial patients will be treated and observed for six weeks; if side effects are not severe, additional subjects will be added at a higher dose. CEL-SCI plans to leverage the clinical trial design of a Phase I study done at the University of Maryland in cervical dysplasia in those co-infected with HIV and HPV, where administration of Multikine resulted in lesion reduction and the elimination of some HPV strains, of which up to150 exist with varying degrees of cancer potential. Importantly, CEL-SCI is not required to relinquish patent rights, does not owe money to the Navy and stands to exclusively license any new technology, if developed.
News 
Market Data 
Discover 
